| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 22, 2017 | SVP, GM - Oncology | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 393 | $16.80 | 18,040 | |
| Jul 22, 2017 | SVP and General Counsel | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 397 | $16.80 | 31,679 | |
| Jul 21, 2017 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $15.79 | 91,683 | |
| Jul 21, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $15.72 | 47,600 | |
| Jul 20, 2017 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 20,000 | $15.64 | 86,683 | |
| Jun 19, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | $15.75 | 56,144 | |
| Jun 19, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 13,544 | $16.28 | 42,600 | |
| Jun 19, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jun 02, 2017 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 647 | |
| Jun 02, 2017 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 3,436 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.